Cargando…
Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study
BACKGROUND: Disentangling the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and vaccination on the occurrence of post-acute sequelae of SARS-CoV-2 (PASC) is crucial to estimate and reduce the burden of PASC. METHODS: We performed a cross-sectional analysis (May/Jun...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371307/ https://www.ncbi.nlm.nih.gov/pubmed/36905145 http://dx.doi.org/10.1093/cid/ciad143 |
_version_ | 1785078119630110720 |
---|---|
author | Kahlert, Christian R Strahm, Carol Güsewell, Sabine Cusini, Alexia Brucher, Angela Goppel, Stephan Möller, Elisabeth Möller, J Carsten Ortner, Manuela Ruetti, Markus Stocker, Reto Vuichard-Gysin, Danielle Besold, Ulrike McGeer, Allison Risch, Lorenz Friedl, Andrée Schlegel, Matthias Vernazza, Pietro Kuster, Stefan P Kohler, Philipp |
author_facet | Kahlert, Christian R Strahm, Carol Güsewell, Sabine Cusini, Alexia Brucher, Angela Goppel, Stephan Möller, Elisabeth Möller, J Carsten Ortner, Manuela Ruetti, Markus Stocker, Reto Vuichard-Gysin, Danielle Besold, Ulrike McGeer, Allison Risch, Lorenz Friedl, Andrée Schlegel, Matthias Vernazza, Pietro Kuster, Stefan P Kohler, Philipp |
author_sort | Kahlert, Christian R |
collection | PubMed |
description | BACKGROUND: Disentangling the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and vaccination on the occurrence of post-acute sequelae of SARS-CoV-2 (PASC) is crucial to estimate and reduce the burden of PASC. METHODS: We performed a cross-sectional analysis (May/June 2022) within a prospective multicenter healthcare worker (HCW) cohort in north-eastern Switzerland. HCWs were stratified by viral variant and vaccination status at time of their first positive SARS-CoV-2 nasopharyngeal swab. HCWs without positive swab and with negative serology served as controls. The sum of 18 self-reported PASC symptoms was modeled with univariable and multivariable negative-binomial regression to analyze the association of mean symptom number with viral variant and vaccination status. RESULTS: Among 2912 participants (median age: 44 years; 81.3% female), PASC symptoms were significantly more frequent after wild-type infection (estimated mean symptom number: 1.12; P < .001; median time since infection: 18.3 months), after Alpha/Delta infection (0.67 symptoms; P < .001; 6.5 months), and after Omicron BA.1 infections (0.52 symptoms; P = .005; 3.1 months) versus uninfected controls (0.39 symptoms). After Omicron BA.1 infection, the estimated mean symptom number was 0.36 for unvaccinated individuals versus 0.71 with 1–2 vaccinations (P = .028) and 0.49 with ≥3 prior vaccinations (P = .30). Adjusting for confounders, only wild-type (adjusted rate ratio [aRR]: 2.81; 95% confidence interval [CI]: 2.08–3.83) and Alpha/Delta infections (aRR: 1.93; 95% CI: 1.10–3.46) were significantly associated with the outcome. CONCLUSIONS: Previous infection with pre-Omicron variants was the strongest risk factor for PASC symptoms among our HCWs. Vaccination before Omicron BA.1 infection was not associated with a clear protective effect against PASC symptoms in this population. |
format | Online Article Text |
id | pubmed-10371307 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-103713072023-07-27 Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study Kahlert, Christian R Strahm, Carol Güsewell, Sabine Cusini, Alexia Brucher, Angela Goppel, Stephan Möller, Elisabeth Möller, J Carsten Ortner, Manuela Ruetti, Markus Stocker, Reto Vuichard-Gysin, Danielle Besold, Ulrike McGeer, Allison Risch, Lorenz Friedl, Andrée Schlegel, Matthias Vernazza, Pietro Kuster, Stefan P Kohler, Philipp Clin Infect Dis Major Article BACKGROUND: Disentangling the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and vaccination on the occurrence of post-acute sequelae of SARS-CoV-2 (PASC) is crucial to estimate and reduce the burden of PASC. METHODS: We performed a cross-sectional analysis (May/June 2022) within a prospective multicenter healthcare worker (HCW) cohort in north-eastern Switzerland. HCWs were stratified by viral variant and vaccination status at time of their first positive SARS-CoV-2 nasopharyngeal swab. HCWs without positive swab and with negative serology served as controls. The sum of 18 self-reported PASC symptoms was modeled with univariable and multivariable negative-binomial regression to analyze the association of mean symptom number with viral variant and vaccination status. RESULTS: Among 2912 participants (median age: 44 years; 81.3% female), PASC symptoms were significantly more frequent after wild-type infection (estimated mean symptom number: 1.12; P < .001; median time since infection: 18.3 months), after Alpha/Delta infection (0.67 symptoms; P < .001; 6.5 months), and after Omicron BA.1 infections (0.52 symptoms; P = .005; 3.1 months) versus uninfected controls (0.39 symptoms). After Omicron BA.1 infection, the estimated mean symptom number was 0.36 for unvaccinated individuals versus 0.71 with 1–2 vaccinations (P = .028) and 0.49 with ≥3 prior vaccinations (P = .30). Adjusting for confounders, only wild-type (adjusted rate ratio [aRR]: 2.81; 95% confidence interval [CI]: 2.08–3.83) and Alpha/Delta infections (aRR: 1.93; 95% CI: 1.10–3.46) were significantly associated with the outcome. CONCLUSIONS: Previous infection with pre-Omicron variants was the strongest risk factor for PASC symptoms among our HCWs. Vaccination before Omicron BA.1 infection was not associated with a clear protective effect against PASC symptoms in this population. Oxford University Press 2023-03-11 /pmc/articles/PMC10371307/ /pubmed/36905145 http://dx.doi.org/10.1093/cid/ciad143 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Article Kahlert, Christian R Strahm, Carol Güsewell, Sabine Cusini, Alexia Brucher, Angela Goppel, Stephan Möller, Elisabeth Möller, J Carsten Ortner, Manuela Ruetti, Markus Stocker, Reto Vuichard-Gysin, Danielle Besold, Ulrike McGeer, Allison Risch, Lorenz Friedl, Andrée Schlegel, Matthias Vernazza, Pietro Kuster, Stefan P Kohler, Philipp Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study |
title | Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study |
title_full | Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study |
title_fullStr | Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study |
title_full_unstemmed | Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study |
title_short | Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study |
title_sort | post-acute sequelae after severe acute respiratory syndrome coronavirus 2 infection by viral variant and vaccination status: a multicenter cross-sectional study |
topic | Major Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371307/ https://www.ncbi.nlm.nih.gov/pubmed/36905145 http://dx.doi.org/10.1093/cid/ciad143 |
work_keys_str_mv | AT kahlertchristianr postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy AT strahmcarol postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy AT gusewellsabine postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy AT cusinialexia postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy AT brucherangela postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy AT goppelstephan postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy AT mollerelisabeth postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy AT mollerjcarsten postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy AT ortnermanuela postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy AT ruettimarkus postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy AT stockerreto postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy AT vuichardgysindanielle postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy AT besoldulrike postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy AT mcgeerallison postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy AT rischlorenz postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy AT friedlandree postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy AT schlegelmatthias postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy AT vernazzapietro postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy AT kusterstefanp postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy AT kohlerphilipp postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy AT postacutesequelaeaftersevereacuterespiratorysyndromecoronavirus2infectionbyviralvariantandvaccinationstatusamulticentercrosssectionalstudy |